Results 151 to 160 of about 130,425 (315)

Supplementary Note from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i>-Mutant Cancers

, 2023
Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, Alexandros Georgiou, Anna Minchom, Suzanne Carreira, David Cunningham, Mary O’Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al‐Lazikani, Udai Banerji   +11 more
openalex   +1 more source

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review). [PDF]

Oncol Rep
Sharma U, Song J, Kandu H, Zhu Y, Dai Z.
europepmc   +1 more source

KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis. [PDF]

BMC Cancer
Kassaw AB, Abera MB, Seid MA, Jemal M, Ahmed H, Asfaw MS, Abebe G, Alem A, Geto Z.   +8 more
europepmc   +1 more source

KRAS Mutation [PDF]

The Journal of Molecular Diagnostics, 2010
Wilbur A. Franklin, Jerry Haney, Michio Sugita, Lynne Bemis, Antonio Jimeno, Wells A. Messersmith   +5 more
openaire   +1 more source

Covalent Guanosine Mimetic Inhibitors of G12C KRAS

, 2016
Yuan Xiong, Jia Lu, John C. Hunter, Lianbo Li, David A. Scott, Hwan Geun Choi, Sang Min Lim, Anuj Manandhar, Sudershan Reddy Gondi, Taebo Sim, Kenneth D. Westover, Nathanael S. Gray   +11 more
openalex   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer. [PDF]

Int J Biol Sci
Li J, Song N, Ma R, Qu X.
europepmc   +1 more source

Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML‐M4 and AML‐M5, Treated With Venetoclax Plus Azacitidine

American Journal of Hematology, EarlyView.
Marina Konopleva, Courtney D. DiNardo, Yan Sun, Paul Jung, Sanam Loghavi, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea   +8 more
wiley   +1 more source

Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

Arthritis &Rheumatology, Accepted Article.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, Jun Xie, Tao Yue, Qi Zhu, Xiaoming Zhang, Lu Xie, Lianbo Xiao   +15 more
wiley   +1 more source

The Missing Link between (Un)druggable and Degradable KRAS [PDF]

, 2020
Elena De Vita, Marı́a Maneiro, Edward W. Tate   +2 more
openalex   +1 more source